Delgocitinib for Hand Eczema Could Save Plans $88M Annually-Lower Cost Than Off-Label Treatments
Delgocitinib, a novel JAK inhibitor, could reduce health plan expenses by $88M over three years for 1M members by replacing off-label therapies for chronic hand eczema, according to new cost ... Read More